title: Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells.
abstract: To date, there are no simple and minimally invasive methods to diagnose MDR. Extracellular vesicles (EVs) are shed by all cells, carry a specific cargo from the donor cells and are present in several body fluids, which means that they can potentially be easily collected from cancer patients and become the source of biomarkers to diagnose cancer. This data article contains a full list of the proteins identified in the EVs shed by an isogenic pair of chronic myeloid leukaemia cells (MDR cells and their drug-sensitive counterparts) by LC/MS/MS analysis, together with their GeneOntology analysis. In addition, it also contains data from protein content analysis and Dynamic light scattering count-rate events of the referred EVs as well as of the EVs shed from an isogenic pair of non-small cell lung cancer cells (MDR cells and their drug-sensitive counterparts). The interpretation of the data presented in this article and further extensive insights can be found in "Multidrug resistant tumour cells shed more microvesicles-like EVs and less exosomes than their drug-sensitive counterpart cells" [1].
authors.affiliation: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-465 Porto, Portugal; ICBAS-UP - Institute of Biomedical Sciences Abel Salazar, University of Porto, 4099-003 Porto, Portugal.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Lopes-Rodrigues
authors.affiliation: NICB - National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
authors.forename: Alessio
authors.initials: A
authors.lastname: Di Luca
authors.affiliation: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-465 Porto, Portugal; Department of Biological Sciences, FFUP - Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
authors.forename: Diana
authors.initials: D
authors.lastname: Sousa
authors.affiliation: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-465 Porto, Portugal.
authors.forename: Hugo
authors.initials: H
authors.lastname: Seca
authors.affiliation: NICB - National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
authors.forename: Paula
authors.initials: P
authors.lastname: Meleady
authors.affiliation: NICB - National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
authors.forename: Michael
authors.initials: M
authors.lastname: Henry
authors.affiliation: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-465 Porto, Portugal; Department of Pathology and Oncology, FMUP - Faculty of Medicine of the University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
authors.forename: Raquel T
authors.initials: RT
authors.lastname: Lima
authors.affiliation: NICB - National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
authors.forename: Robert
authors.initials: R
authors.lastname: O'Connor
authors.affiliation: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-465 Porto, Portugal; Department of Biological Sciences, FFUP - Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
authors.forename: M Helena
authors.initials: MH
authors.lastname: Vasconcelos